Chronic Kidney Disease: A Rising Global Concern
Chronic kidney disease (CKD) has now emerged as the ninth leading cause of death worldwide, according to new findings from a comprehensive study. Researchers from NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington highlighted a significant increase in the number of people facing reduced kidney function.
The team analyzed over 2,230 studies from 133 different countries, focusing on the diagnosis, death rates, and disabilities associated with kidney disease. The results are alarming: cases of CKD have soared from 378 million in 1990 to 788 million by 2023, marking its first appearance in the top ten of the most deadly diseases globally.
The Global Burden of Disease 2023 study reveals that about 14% of adults worldwide are affected by CKD. Tragically, around 1.5 million deaths were reported in 2023 due to kidney disease, which represents a 6% increase since 1993. Most individuals diagnosed are in the early stages of the disease, where timely medications and lifestyle changes can help avoid severe interventions like dialysis or surgery.
This extensive research was shared at the recent American Society of Nephrology’s annual Kidney Week conference and is described as one of the most detailed assessments of CKD in nearly a decade.
Chronic kidney disease hinders the kidneys’ ability to filter waste and excess fluids from the blood. While early stages may often go unnoticed, advanced CKD may necessitate dialysis or even a kidney transplant. Moreover, compromised kidney function has been associated with a heightened risk of heart disease, contributing to approximately 12% of global cardiovascular deaths. Major risk factors identified include high blood sugar, high blood pressure, and obesity.
Dr. Josef Coresh, a leading author of the study, categorizes CKD as a prevalent and serious public health issue that requires urgent attention from policymakers, similar to cancer and heart disease.
Dr. Morgan Grams, another key study author, emphasizes that CKD is frequently overlooked during diagnosis and treatment. She advocates for increased urine testing to detect the disease early and better access to effective therapies for patients who are diagnosed.
New treatments that can slow the progression of CKD and lessen the risk of heart-related issues are now available, though their wider impact will take time to achieve.
In commentary on the findings, Dr. Marc Siegel, a senior medical analyst, voiced concern over the underestimation and underdiagnosis of CKD. He pointed out that various health issues, such as high blood pressure, obesity, and diabetes, significantly affect kidney function.
This significant study has received funding from the National Institutes of Health, the Gates Foundation, and the National Kidney Foundation, underlining the importance of addressing this growing health challenge.
